ニュース、リソース、最新情報
当社の最新の研究動向や企業情報をお届けする科学情報拠点です。
腫瘍微小環境（TME）の多重免疫表現型解析
The use of preclinical orthotopic tumors to better recapitulate the tumor microenvironment (TME) Complex interactions between the cellular and structural components of the tumor microenvironment (TME) composed of tumor cells, fibroblasts, endothelial cells, immune...
脊髄損傷（SCI）マウスモデルの特性解析
Spinal cord injury (SCI) is a condition mainly resulting from traumatic injuries caused by falls, or (road traffic) accidents. Currently, many novel therapeutics ranging from small molecules, (stem) cell transplants to medical devices are evaluated for their efficacy...
Relevant pharmaco-EEG in vivo data (Baclofen, Fenfluramine)
Currently, preclinical neuroscience research calls for more translationally relevant biomarkers that help better predict clinical outcomes. Electrophysiological events recorded via electroencephalography (EEG) recordings, highly utilised in the clinic, arise as...
サルサレートは、ADPKDマウスモデルにおいて疾患の進行を抑制する
In this newsletter we present in-house validation data of Salsalate on disease progression in the ADPKD mouse model. One of key therapeutic strategies undertaken to provide new and efficacious treatments for ADPKD is targeting key signaling pathways that drive cystic...
関連する生体内研究およびin vitro免疫腫瘍学アッセイ
Drug efficacy in vivo studies At InnoSer, we frequently carry out in vivo efficacy studies in a range of preclinical models (patient-derived xenografts, syngeneic models, cell-line derived xenografts) complemented with readouts such immune cell profiling and...
ADPKDマウスモデルにおける疾患進行の評価
A significant challenge in the ADPKD research field is demonstrating efficacy of novel compounds in preclinical research models using clinically relevant endpoints. To date, total kidney volume (TKV) is the only FDA and EMA-approved imaging biomarker that is used as a...
info@innoserlaboratories.com